Tag: ASCO 2026

Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.